Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

‘We launched with a pretty mediocre product’ — how two direct-to-consumer startups iterated to success

Customer feedback is very important.

Native founder and CEO Moiz Ali (center) and JT Marino (right), co-founder of Tuft & Needle, at Code Commerce in New York City 
Native founder and CEO Moiz Ali (center) and JT Marino (right), co-founder of Tuft & Needle, at Code Commerce in New York City 
Native founder and CEO Moiz Ali (center) and JT Marino (right), co-founder of Tuft & Needle, at Code Commerce in New York City
Keith MacDonald for Vox Media
Rani Molla
Rani Molla was a senior correspondent at Vox and has been focusing her reporting on the future of work. She has covered business and technology for more than a decade — often in charts — including at Bloomberg and the Wall Street Journal.

First is the worst — at least when it comes to consumer goods. That’s the message from the founders of deodorant and mattress brands Native and Tuft & Needle.

“We launched with a pretty mediocre product,” Native deodorant CEO and founder Moiz Ali told the crowd at Code Commerce in New York City. How did he know? Customers said so. They also didn’t buy the product again and gave bad reviews.

“We quickly realized there was a need for a better-for-you deodorant and customers were willing to pay a higher price for it, but we also realized we didn’t have that product,” Ali said. “So the first year of business was just us trying to figure out how to make a better product.” That involved sending different samples to different customers and acting on the feedback they got.

“In May 2016, we launched a better formula and we quintupled revenue between May and December because we had a better formula,” Ali said. “Customers told us that.”

JT Marino, co-founder of Tuft & Needle, had a similar experience with his mattress brand.

“That was never our expectation, that our first version would be the one,” Marino said. “Our background is in technology, and what you learn in software and technology production is ‘release early and release often,’ and iterate based on customer feedback as fast as you can.”

The result? Tuft & Needle’s return rate went from the double digits to “one of the industry’s lowest, if not the lowest.”

Watch the full interview below:

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh